A New Look at the Dose-Response Relationship in Phase 1 Oncology Trials
The new generation of cancer drugs behave quite differently than cytotoxic therapies, and that may mean phase 1 trials need to be updated.
Chronic Myeloid Leukemia
Researchers Turn to Crowdsourcing to Learn More About COVID-19 and Cancer
Pooling data from physicians and patients appears to be an efficient way to answer urgent questions.
Early Monitoring of Chronic Myeloid Leukemia Might Dictate TKI Switch
Lack of initial response to imatinib might indicate need to switch to dasatinib.
Not Developing Any New Drugs Could Be EQRx’s Biggest Innovation
The best bet for a new company hoping to deliver on a lofty promise to “remake medicine” could rely on drug repurposing.
“Medical Distancing” May Help Protect Cancer Patients From Exposure to COVID-19
Screening patients by phone before they come to a clinic may help to eliminate potentially redundant visits and lower the risk of infection.
Federal Ruling Puts Pressure on Clinical Trial Sponsors to Post Data
A federal ruling will force trial sponsors to post basic results on ClinicalTrials.gov, but it is unclear whether this is a feasible mandate.
First Human Clinical Trial in US to Test the Use of CRISPR-Modified T Cells in Cancer Answers Vital Questions
CRISPR-modified T cells were used in 3 patients with advanced cancer for the first time, showing modest results on tumor growth.
Improving Cancer Pain Management Amid the Opioid Crisis
Research into opioid alternatives for cancer-related pain has stalled, however substance use disorders remain problematic.
A New Trend in Drug Development: Leveraging Data from Expanded Access
Drug companies are gathering and including expanded access data in drug submissions as real-world data, but the purpose of expanded access was never for the purpose of research.
The Questionable Practice That Permeates Oncology Clinical Trials
Most oncology phase 1 trials use a simplistic, outdated dose-finding technique, and experts agree that change is needed.
-
Loading...
-
Loading...
Next post in General Oncology
